Pregled bibliografske jedinice broj: 1182676
Antifosfolipidni sindrom - prikaz slučaja
Antifosfolipidni sindrom - prikaz slučaja // Biochemia Medica2018 ; 28(Suppl 1):S1-S223
Zagreb, 2018. str. S54-S55 (poster, domaća recenzija, sažetak, stručni)
CROSBI ID: 1182676 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Antifosfolipidni sindrom - prikaz slučaja
(Antiphospholipid syndrome - case report)
Autori
Fijačko, Mirjana ; Glasnović, Marija ; Milić, Marija ; Pavela, Jasna ; Dobrošević, Blaženka ; Šahinović, Ines ; Šerić, Vatroslav
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, stručni
Izvornik
Biochemia Medica2018 ; 28(Suppl 1):S1-S223
/ - Zagreb, 2018, S54-S55
Skup
9. kongres hrvatskog društva za medicinsku biokemiju i laboratorijsku medicinu (HDMBLM)
Mjesto i datum
Zagreb, Hrvatska, 09.05.2018. - 12.05.2018
Vrsta sudjelovanja
Poster
Vrsta recenzije
Domaća recenzija
Ključne riječi
antifosfolipidni sindrom, antifosfolipidna antitijela
(antiphospholipid syndrome, antiphospholipid antibody)
Sažetak
Introduction: The antiphospholipid syndrome (APS) is defined by the persistent presence of antiphospholipid antibodies (aPLS) with a variety of clinical phenotypes, including venous or arterial thrombosis, recurrent pregnancy loss and thrombocytopenia. It can be a primary disease or secondary when associated with other autoimmune diseases. Laboratory diagnosis of aPLS is based on the detection of lupus anticoagulant (aLA), and/or anticardiolipin (aCL) and anti-ß2-glycoprotein-1 (aß2G-1) antibodies. Pathophysiologic mechanisms in APS include aPLS induced cellular activation (predominantly with aß2G-1), inhibition of natural anticoagulant and fibrinolitic systems, and complement activation. Subjects and methods: The aim of the study was to review the clinical manifestations of the APS and the antibody titers of aPLS in a 45-year-old women with diagnosed primary APS at the age of 30, according to classification criteria of International Consensus for diagnosis and therapeutic strategies in patients affected by APS. The patient was diagnosed with secondary APS only 8 years after the onset of the disease. Results: Through this case report, we describe the evolution of its complex pathology over a 15-year period of follow-up: obstetric complications - spontaneus abortion, psoriasis, psoriatic arthritis, cerebral demyelinization, APL nephropathy - trombotic microangiopathy, hypertension, hereditary thrombophilia, colagenosis mixta, anaemia, thrombocytopenia, hemiparesis. We had triple positive antibodies: aLA was always positive, aCL and especially aß2G-1 antibodies concentrations were highly elevated. Concentrations of C3 and C4 component of complement were permanently reduced, titers of antinuclear antibodies (ANA) were negative. Biochemia Medica 2018 ; 28(Suppl 1):S1–S223 S55 Conclusion: We conclude that high values of aPLS in APS, in particular anti-ß2-glycoprotein-1 antibodies, can be the cause of numerous pathological clinical manifestations. Long-term monitoring is important for identifying laboratory parameters that may portend the development of further autoimmune symptoms associated with APS.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti, Biotehnologija u biomedicini (prirodno područje, biomedicina i zdravstvo, biotehničko područje)
POVEZANOST RADA
Ustanove:
Klinički bolnički centar Osijek,
Medicinski fakultet, Osijek
Profili:
Ines Šahinović
(autor)
Mirjana Fijačko
(autor)
Marija Milić
(autor)
Marija Glasnović
(autor)
Vatroslav Šerić
(autor)